Clinical Trial Update: Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age [Phase 2]

View source ↗

Summary

Phase 2 trial comparing MMRV vaccine from GlaxoSmithKline to ProQuad in children 12-14 months, assessing immunogenicity and safety for varicella and rubella (li…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Measles
• Mumps
• Rubella
• Varicella

Drugs mentioned

• MMRV vaccine (Measles, Mumps, Rubella, Varicella Vaccine)
• ProQuad (Measles, Mumps, Rubella and Varicella live attenuated vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Varicella, Rubella | Phase 2 | Status: COMPLETED | Results posted: 2010-08-26